CMI
Burlingame, CA, June 18, 2025 (GLOBE NEWSWIRE) — The Coherent Market Insights reveals that the Critical Limb Ischemia Treatment Market is estimated to be valued at USD 5.55 Bn in 2025 and is expected to reach USD 10.02 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032. The critical limb ischemia treatment market is projected to experience significant growth during the forecast period. Key factors driving this expansion include the increasing global geriatric population and the rising prevalence of peripheral artery disease, both of which are contributing to a growing demand for effective treatment options.
Get a Sample Pages of Critical Limb Ischemia Treatment Market @ https://www.coherentmarketinsights.com/insight/request-sample/7115
Global Critical Limb Ischemia Treatment Market Key Takeaways
According to Coherent Market Insights (CMI), the global critical limb ischemia market size is projected to expand at a CAGR of 8.8%, growing from USD 5.55 Bn in 2025 to USD 10.02 Bn by 2032.
Based on drugs, antihypertensive agents category is expected to dominate the market, generating a revenue of around USD 1.69 Bn in 2025.
By route of administration, parental segment is anticipated to account for more than three-fifths of the global critical limb ischemia treatment market share in 2025.
By end user, hospitals segment will likely hold a prominent market share of over 2/5 by 2025.
As per Coherent Market Insights’ new critical limb ischemia treatment market analysis, North America is set to account for a market share of more than two-fifths in 2025.
Asia Pacific critical limb ischemia treatment market is expected to experience fastest growth throughout the assessment period.
Rising Prevalence of Diabetes and Peripheral Artery Disease Fueling Market Growth
Coherent Market Insights’ latest critical limb ischemia treatment market report highlights key factors driving the industry’s growth. One such prominent growth factor is the increasing incidence of diabetes and peripheral artery disease (PAD).
According to the CLI Global Society, more than 202 million adults worldwide are affected by PAD—a number expected to rise due to the growing global burden of diabetes. Since diabetes is a major risk factor for PAD and CLI, this trend is anticipated to significantly boost demand for critical limb ischemia treatments.
Patients with critical limb ischemia, a severe form of PAD, are commonly treated with medications like antihypertensive agents and antithrombotic agents. As the number of PAD cases increases, so will demand for effective CLI treatments.